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Brief Review
Report of the National Heart, Lung, and Blood Institute
Working Group on Epigenetics and Hypertension
Allen W. Cowley, Jr, Joseph H. Nadeau, Andrea Baccarelli, Kathleen Berecek, Myriam Fornage,
Gary H. Gibbons, David G. Harrison, Mingyu Liang, Peter W. Nathanielsz, Daniel T. O’Connor,
Jose Ordovas, Weiqun Peng, Marcelo Bento Soares, Moshe Szyf, H. Eser Tolunay, Katherine C. Wood,
Keji Zhao, Zorina S. Galis
Human and Financial Impact of
Essential Hypertension
Hypertension, defined as a condition associated with 140-
mmHg systolic blood pressure or90-mmHg diastolic blood
pressure, affects 1 billion people worldwide,1 and in 2009
it cost the US healthcare system more than $73 billion.2
Despite the availability of many antihypertensive therapies,
individual responses vary, and efficacy remains a concern.
Current treatments have yielded only modest reductions in
the overall disease risk even in countries where therapeutics
are available and affordable. The initiating causes and the
pathogenic mechanisms for disease and its comorbidities
remain largely unknown, and prognostic markers for adult
hypertension that could improve its diagnosis, prevention,
and, ultimately, its management are not yet available. As a
result, 28% of the US population and a similar proportion
of the adult Western European and Canadian populations
experience what is known as “essential hypertension,”3 which
is a primary component of several complex, multifactorial,
multigenic conditions that are commonly associated with
high levels of morbidity and mortality from diabetes mellitus,
cardiovascular disease, and renal disease. If the current rise in
the number of hypertension cases is not abated, total annual
global healthcare costs resulting from suboptimal blood
pressure for those 30 years of age could amount to $3.6
trillion more over the next 10 years.4
Genetics, “Missing Heritability,” and the
Epigenetic Hypothesis
The causes of essential hypertension remain poorly under-
stood, although the complex mechanisms for blood pressure
(BP) regulation have been extensively characterized in both
humans and animal models.5–7 Comprehensive study of 12
inbred rat strains that recapitulate many aspects of hereditary
human hypertension has added substantially throughout the
years to our understanding of the underlying physiological
and molecular pathways, the genetic complexity of risk and
treatment responses, and the pathological consequences of
hypertension.8 In fact, many interventions that lead to a
lowering of BP were identified first with these experimental
model systems.9,10 Detailed annotations of such experimental
models are currently available (PhysGen Knockout Program,
http://rgd.mcw.edu). These studies in experimental models
are, however, only the first step in the quest to clarify the
genetic and phenotypic architecture of this complex human
disease.11–15
Hypertension is a highly heritable trait,16,17 and recent
genome-wide linkage and association studies, as well as
candidate gene approaches, clearly demonstrate the multi-
genic complexity of essential hypertension.18–22 The Interna-
tional Consortium for Blood Pressure Genome-Wide Associ-
ation Studies, which used a multistage design in 200000
individuals of European descent, recently identified 16 novel
functional genetic variants, associated with high BP in human
Received December 21, 2011; first decision January 4, 2012; revision accepted February 28, 2012.
From the Department of Physiology (A.W.C., M.L.), Cardiovascular Center (A.W.C.), Medical College of Wisconsin, Milwaukee, WI; Institute for
Systems Biology (J.H.N.), Seattle, WA; Laboratory of Environmental Epigenetics (A.B.), Exposure Epidemiology and Risk Program, Departments of
Environmental Health and Epidemiology, Harvard School of Public Health, Boston, MA; Department of Physiology and Biophysics (K.B.), University
of Alabama at Birmingham Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, AL; Institute of Molecular Medicine
(M.F.), University of Texas Health Science Center at Houston, Houston, TX; Cardiovascular Research Institute (G.H.G.), Morehouse School of Medicine,
Atlanta, GA; Clinical Pharmacology (D.G.H.), Vanderbilt School of Medicine, Nashville, TN; Center for Pregnancy and Newborn Research (P.W.N.),
Department of Obstetrics/Gynecology, University of Texas Health Science Center at San Antonio, San Antonio, TX; Department of Medicine (D.T.O.),
University of California at San Diego, San Diego, CA; US Department of Agriculture Human Nutrition Research Center on Aging (J.O.), Tufts University,
Boston, MA; Department of Epidemiology and Population Genetics (J.O.), Centro Nacional Investigación Cardiovasculares, Madrid, Spain; IMDEA
Alimentacion (J.O.), Madrid, Spain; Department of Physics (W.P.), George Washington University, Washington, DC; Children’s Memorial Research
Center (M.B.S.), Falk Brain Tumor Center, Northwestern University, Chicago, IL; Department of Pharmacology and Therapeutics (M.S.), McGill
University, Montreal, Quebec, Canada; Division of Cardiovascular Sciences (H.E.T.), Hematology Branch (K.C.W.), Division of Intramural Research
(K.Z.), and Division of Cardiovascular Sciences (Z.S.G.), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
A.W.C. and J.H.N. contributed equally to this work.
Correspondence to Allen W. Cowley, Department of Physiology, Cardiovascular Center, Medical College of Wisconsin, 8701 Watertown Plank Rd,
Milwaukee, WI 53226 (E-mail cowley@mcw.edu); or Joseph H. Nadeau, Institute for Systems Biology, 401 Terry Ave North, Seattle, WA 98109 (E-mail
jnadeau@systemsbiology.org).
(Hypertension. 2012;59:899-905.)
© 2012 American Heart Association, Inc.
Hypertension is available at http://hyper.ahajournals.org DOI: 10.1161/HYPERTENSIONAHA.111.190116
899 at UniversitÃ  degli Studi di Milano on July 11, 2012http://hyper.ahajournals.org/Downloaded from 
populations.20 (These variants are commonly known as quan-
titative trait loci.) Six of these loci involve genes known
previously or suspected to regulate BP, with the other genetic
variants pointing to novel pathways that influence BP and
cardiovascular disease risk.
An unexpected and disconcerting observation from these
genetic studies is that the discovered genetic variants, indi-
vidually and collectively, account for only a small fraction of
phenotypic variation and disease risk. For example, these BP
quantitative trait loci together account for only a small
proportion of BP variation (5 mmHg), yet their typical
effect size is sufficient to raise cardiovascular disease risk in
human populations.18–22 Importantly, although the Cohorts
for Heart and Aging Research in Genomic Epidemiology and
Global Blood Pressure Genetics (Global BPgen) consortia
established and replicated the effects of 8 novel loci on BP,
the cumulative effect of these 8 loci explained only 1% of
BP variance.18,19 These results are especially surprising given
the substantial heritability of BP, estimated between 30% and
40%.15,16 Similar results have emerged in genome-wide
linkage and association studies of other complex conditions
in humans and genetic studies of other species.11–15 This
difference between estimated and observed variance is
termed “missing heritability,” the search for which has now
become one of the primary goals for research on hypertension
and other complex conditions.11
To explain the missing heritability of complex traits,
several hypotheses have been proposed, including overes-
timates of heritability, unexplored regions of the genome,
untested classes of genetic variants, the action of many
rare genetic variants, and gene interactions.11,23,24 Pheno-
typic variation can also be regulated independent of
changes in DNA sequence, thereby escaping detection with
classic genetic approaches.25–31 These heritable epigenetic
changes could explain some of the missing heritability in
hypertension, and some circumstantial evidence involving
modification of genes that could affect important pathways
in hypertension is beginning to emerge, further prompting
the need for experiments specifically designed to prove a
causal relationship.32
Epigenetics
“Epigenetics” is defined as the transmission from one cell
generation to the next (through mitosis) or from one organ-
ismal generation to the next (through meiosis) of gene
expression patterns that do not rely explicitly on differences
in DNA sequence.25 The term was originally introduced to
account for the maintenance of cell- and tissue-specific gene
expression patterns across mitotic cell divisions throughout
somatic development. Many cell functions, such as tissue
specificity, germline specificity, imprinting, and X-chromosome
inactivation, rely on correct epigenetic control of gene ex-
pression.30,31 Introduction of high-throughput technologies,
which now enable epigenetic features to be comprehensively
and quantitatively profiled across the genome, has led to
exciting evidence in animal models where epigenetic changes
have been documented not only during development but also
in adult conditions, such as cancer,33 cardiovascular dis-
ease,34 diabetes mellitus,35 obesity,36 and longevity.37 Evi-
dence for epigenetic effects in humans is more limited
because of the considerable challenges in study design
needed to reliably distinguish the various sources of pheno-
typic variation. As a result, many questions remain, such as
defining the environmental and genetic factors that trigger
epigenetic changes; defining the molecular mechanisms that
maintain and, where necessary, reverse epigenetic features;
assessing the relative contributions of genetic, environmental,
and epigenetic factors; and characterizing the impact of
epigenetic changes on phenotypic variation and disease risk
within and across generations.
Epigenetic changes are orchestrated by several molecular
processes, including nucleic acid methylation, histone modi-
fication, nucleosome positioning, transcription control with
DNA binding proteins and noncoding RNAs, and translation
control with microRNAs and RNA binding proteins.26–31 Of
the many modes of epigenetic control, the best studied are
histone modification and DNA methylation. Histone modifi-
cation is an important mechanism that leads to changes in the
nucleosome to constrain DNA wrapping around its histone
core (nucleosome positioning). Chemical modification of the
N-terminal tails of histone proteins forms a “histone code”
that regulates gene activity. DNA methylation is another
important mechanism of epigenetic control in which methyl-
ation of DNA occurs at the cytosine base of DNA, often in the
context of CpG dinucleotides. In addition, other forms of
chemically modified DNA have been reported recently.26 An
important but less studied mode of epigenetic control in-
volves noncoding-RNAs (microRNAs as well as other long
and short RNAs) that regulate gene expression and mRNA
translation. Systematically characterizing these various kinds
of epigenetic marks across the genome, during development
and throughout the life of an organism, is a major challenge,
as is dealing with cellular and temporal heterogeneity in these
marks.
Studies in experimental animals show that epigenetic
changes can arise throughout life, from early embryos to old
age, as a result of developmental and physiological processes,
environmental exposure, and stochastic events. The epig-
enome is thought to be most vulnerable to modification
during embryogenesis when DNA synthesis is rapid and
when both DNA methylation patterns and chromatin structure
required for normal development are established. During
development, for example, maternal nutritional status, as well
as altered hormonal and stress profiles, can profoundly affect
epigenetic features with long-term impacts on disease risk. In
addition, studies in twins at different ages show that, although
identical at birth, the epigenome diverges during the life-
time.38 An understanding of the mechanisms that transmit
environmental and genetic signals to the molecular machin-
ery responsible for epigenetic changes that will undoubtedly
emerge would mechanistically explain the molecular embed-
ding of early childhood experiences (“nurture”) onto the
genome (“nature”).39
In many organisms, some epigenetic changes are not erased
during gametogenesis and can affect the phenotype and health
not only of immediate offspring but also of future generations
through transgenerational effects.27–30,40–48 Several studies in
rodents and other species have revealed remarkable evidence
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for heritable epigenetic changes where the phenotypic effects
of environmental exposure and genetic variants can be
transmitted epigenetically across multiple generations. In
some circumstances, these effects can be as strong as con-
ventional genetic effects, endure across multiple generations,
transmit through the male or the female germ lineage, and
reverse under certain conditions.44,45 Epigenetic inheritance
is usually determined by a combination of genetically con-
trolled susceptibility of the parental genome to various
stressors and the vulnerability of the offspring’s genome to
these inherited epigenetic changes. Such changes enable
homeostatic adaptations of the epigenetic code in response to
various environmental and genetic stressors within a parent’s
lifetime to be communicated to the offspring as “preadapta-
tions” to the particular environment in which they live and the
family to which they belong.27,28,49–52
Role of Epigenetics in Hypertension
Many questions emerge from these considerations. Are
epigenetic marks and features a cause or consequence of
hypertension? Do epigenetic changes contribute to comor-
bidities of hypertension, such as diabetes mellitus, cardio-
vascular disease, and renal disease? Are epigenetic fea-
tures indicative of prognostic or diagnostic biomarkers for
human hypertension? Are epigenetic marks of hyperten-
sion fixed early in life rather than changing dynamically in
response to various perturbations? To what extent are these
epigenetic features reversible in a general or in a targeted
manner? What is the molecular basis for epigenetic mem-
ory related to hypertension within and across multiple
generations, how are these marks established, and how do
they differ from other epigenetic features?
In parallel with studying conventional epigenetic features,
such as methylation profiles and histone modification, impor-
tant insights could be gained from investigating the effects of
environmental perturbations on mRNA, microRNA, and non-
coding RNA expression patterns and their potential associa-
tions with the physiological changes during tissue and organ
development, as well as disease initiation and progression.
The working group prioritized 3 questions that require
immediate attention, as follows.
Do Epigenetic Changes Affect BP in Humans?
A deeper understanding of epigenetic changes in response to
environmental and genetic stresses is needed to generate
hypothesis-driven experimental studies that can, in turn,
establish causality and reveal fundamental molecular mech-
anisms of BP regulation. For instance, studies are urgently
needed to establish the chronological sequence of epigenetic
and pathological changes at different life stages (preconcep-
tion, conception, development, birth, childhood, adolescence,
and adulthood) both during normal development and during
the onset and progression of hypertension. With model
organisms, experiments can be designed to rigorously char-
acterize all life stages, obtain diverse organs and tissues for
analysis, and control age, sex, and environment factors. In
parallel, human studies could examine phenotypic discor-
dances within monozygotic (identical) twin pairs, which may
provide a unique window into epigenetic control of BP.
Comparative genetic studies need to take advantage of the
strong evolutionary conservation of DNA methylation and
histone folding in species such as rats, mice, rhesus monkeys,
and humans.53 Epigenetic marks that are not shared among
humans and animal models could point to biological path-
ways and molecular mechanisms that may be highly relevant
to human hypertension. Finally, advantage should be taken of
the rich resources of inbred rodent models of hypertension
and well-characterized consomic, congenic, and recombinant
inbred strains in which many allelic variants have been
captured. Together these integrated studies are essential to
establish basic principles of epigenetic mechanisms in health
and disease, as well as to meaningfully translate epigenetic
research into clinical practice.
What Are the Relative Contributions of
Epigenetic, Genetic, and Environmental
Factors to the Development of Hypertension
and Its Comorbidities?
Assessing the relative contribution of genetic, epigenetic, and
environmental factors to hypertension is urgently needed.
Studying large families in which hypertension segregates in
members exposed to similar environments and diets would be
highly informative. For instance, answers could be sought by
investigating several large, genetically and phenotypically
characterized human cohorts together with family and twin
studies to establish the patterns of covariation among genetic
variants, epigenetic factors, and physiological phenotypes.
Monozygotic (identical) and dizygotic (fraternal) twin studies
allow estimation of the role of heredity on the determination
of many traits.54 Perturbations that provoke disease, together
with modeling of the molecular and physiological networks
and pathways aimed at predicting, identifying, and manipu-
lating causality factors, will be key elements in these studies.
Such approaches need to distinguish between epigenetic
changes that may be simply indicative of disease, for exam-
ple, diagnostic markers, versus those playing a causal role in
the development and maintenance of hypertension in re-
sponse to specific environmental challenges. Parallel studies
in several different environments with various perturbations
will be needed in both animal models and humans to establish
general versus context-dependent relationships. All of these
provide good opportunities to quantify the relative contribu-
tions of genetic variants and epigenetic factors to various
forms of essential hypertension that can be addressed under
defined environmental conditions.
Are Epigenetic Changes Related to Hypertension
Heritable, Do They Accumulate Across
Generations, and Can They Be Reversed?
Recent evidence shows transgenerational inheritance of
environmental and genetic influences on diverse pheno-
types and disease risks. Considerable epidemiological and
experimental evidence in model organisms and, to a lesser
extent, in humans show that the consequences of environ-
mental exposures and genetic variants can be transmitted
for at least several generations after exposure. Under these
conditions, establishing the origins of disease resulting
from the action of genetic variants in ancestral generations
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would be difficult to detect among affected individuals in
a traditional genome-wide linkage and association study.
In addition to contributing to hypertension risk, heritable
epigenetic changes may accumulate across generations and
could account for the dramatic increase in hypertension,
obesity, and related metabolic conditions. Animal models
are especially important to establish principles of study
design, candidate molecular features, and relevant physiolog-
ical functions to validate in humans. Genotype-phenotype
associations could also be tested across generations in se-
lected human populations.
The working group recognizes that these proposals raise
considerable challenges. Epigenetic studies, especially those
that involve transgenerational effects, will be complicated in
humans because of issues related to study design, statistical
power, environmental and genetic heterogeneity among fam-
ilies and populations, and the dynamic nature of epigenetic
changes compared with the stability of DNA sequences.
Studies with animal models face similar challenges. In
addition, physiological and pharmacological research has
made important contributions to treatment, and studies of
both monogenic and multigenic variation have provided
important insights about molecular functions and patho-
genic mechanisms. However, substantial problems remain
for BP management. Integrating epigenetic studies with
ongoing studies may lead to breakthroughs in our under-
standing of BP control.
Current Needs, Resources, and Future
Directions of Research
The National Heart, Lung, and Blood Institute Working
Group identified a remarkable number of currently existing
molecular, genomic, physiological, and computational tools
and approaches that could meaningfully move this field
forward. The working group also identified several important
technology needs.
Over the past decade, many genomic and proteomic databases
and technologies have been developed. These databases enable
systematic collection, storage, and distribution for research of
tissues and cells. Appropriate databases of patient information,
including their genetics, lifestyle, clinical history, and other
relevant information, have also emerged. Similar databases are
related to studies of model organisms so that efficient compar-
ative analyses are increasingly feasible. Numerous experimental
models are already available and continue to be developed as
information resources for many aspects of mouse genetics and
biology, including the National Institutes of Health–funded
initiative the Knockout Mouse Project (http://www.nih.gov/
science/models/mouse/knockout), the Mouse Genome Database
(http://www.informatics.jax.org), and the Mouse Phenome Da-
tabase (www.phenome.jax.org). The Rat Genome Database
(http://rgd.mcw.edu) contains all of the genomic rat model
systems, including inbred, consomic, and knockout strains.
Other resources help researchers identify appropriate model
organisms, for example, Link Animal Models to Human Disease
(http://www.lamhdi.org); existing clinical cohorts (eg, http://web.
chargeconsortium.com); or access other information relevant for
the relation between genotype and phenotype, for example, the
Genotypes and Phenotypes database (http://www.ncbi.nlm.nih.
gov/gap). A specific catalogue enabling inquiries on the parent-
of-origin effects and imprinting in mice can be found at
http://igc.otago.ac.nz/home.html. Databases, as well as analytic
and graphical tools that specifically enable investigation of new
levels of regulation and complexity associated with epigenetic
studies, will need continuous development and wide availability
to facilitate data mining. Computational methods to manage
large genomic data sets are becoming increasingly sophisticated.
Such tools can integrate information from various levels of
functionality that include DNA sequence, RNA expression,
protein isoforms, and their posttranslational modifications of
cell, tissue, organ, and organismal phenotypes, as well as
lifestyle, environmental, dietary, and microbial information.
Particularly urgent research needs include the development
of new technologies to assess epigenetic features in single
cells in vitro and in specific cell types in vivo. Surrogate
markers in blood cells must also be identified as a way to
interrogate cell populations that are generally inaccessible for
direct analysis in humans. Finally, technologies are needed to
modulate epigenetic changes with greater specificity than
genome-wide targeting.
Summary
The working group concluded that epigenetics research
should incorporate multispecies comparisons to benefit from
evolutionary insights and perspectives. Studies will require
coordination of multidisciplinary teams combining expertise
in clinical and basic research, as well as in computational and
modeling methods. New insights and hypotheses will be
generated through genomic and epidemiological surveys,
including leveraging existing clinical and epidemiological
cohorts, experimental animal models, and biological materi-
als to test in new experimental and clinical studies. Study
designs will need to be based on sufficient statistical power to
handle the likely complexity associated with the heteroge-
neous causes and consequences of epigenetic changes. Phe-
notyping at a comparable level of rigor, accuracy, and detail
as surveys of epigenetic features will be required. Multiple
levels of functionality, from cells to the intact organism,
should be studied, and the use of several modalities for
inducing experimental hypertension in various model sys-
tems would help establish general versus context-specific
principles. Finally, such endeavors will require the use and
continued development of technologies that enable rigor-
ous and quantitative measures of epigenetic and physio-
logical changes.
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